A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Bibliographic Details
Main Authors: Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Format: Online
Language:English
Published: BioMed Central 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979046/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979046/

Similar Items